PF-Atlas › Clinical Trials › NCT05671835

Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis

TTI-101 · Phase 2

Registry ID

NCT05671835

Phase

Phase 2

Status

Completed

Drug / intervention

TTI-101

Sponsor

Tvardi Therapeutics, Incorporated

Start

2023-05-15

About this trial

TTI-101 is evaluated in NCT05671835, a Phase 2 idiopathic pulmonary fibrosis study sponsored by Tvardi Therapeutics, Incorporated. Current status: Completed.

View NCT05671835 on ClinicalTrials.gov →

Explore related

All TTI-101 trials All IPF trials

Medical disclaimer. This page summarizes public trial data for NCT05671835 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.